Dendritic
Cell and Tumor Cell Cancer Vaccines Market, by Antigen (CD8, CD4, HER2,
T-Helper Cell, and Others), by Application (Glioblastoma Cancer, Prostate
Cancer, Pancreatic Cancer, Colorectal Cancer, Renal Cancer, Lung Cancer, and
Others) by Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and
Online Pharmacies), and by Region (North America, Latin America, Europe, Asia
Pacific, Middle East, and Africa) – Size, Share, Outlook, and Opportunity
Analysis, 2019 – 2027
Cancer is an abnormal growth of
cells in the body, also known as malignancy. It has the potential to replicate
itself rapidly and invade into other body parts also. There are numerous types
of cancer present. Dendritic cells (part of neuron) plays an important role in
inducing anti-tumor activity. Hence, various strategies are being developed to
treat cancer with the help of dendritic cell. For generation of dendritic
vaccine, dendritic cells are cultured alongside the cancer cells. The vaccine,
when induced into body stimulates the immune system to attack cancer cells.
Global Dendritic Cell and Tumor
Cell Vaccines Market Drivers
Increase in research and
development activities related to dendritic cell and tumor cell based vaccines
are expected to accelerate the global dendritic cell and tumor cell vaccines
market growth. For instance, in March 2015, Rockefeller University and Memorial
Sloan Kettering Cancer Center conducted a phase II study of autologous
dendritic cell vaccines (DC/PC3). It is being used as an immunotherapy in the
prostate cancer. The vaccine was developed by patient’s own cells.
* The sample copy includes: Report Summary, Table of
Contents, Segmentation, Competitive Landscape, Report Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2753
Furthermore, in April 2016,
Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (I.R.S.T.)
S.r.l., began its study on autologous dendritic cells loaded with autologous
tumor homogenate in combination with the drug IL-2. It is being used for the
treatment of patients with stage IV colorectal cancer. The purpose of study is
to evaluate the consistency of the response of immune cells after completion of
the treatment. Currently, the study is in its second phase of clinical trials.
Hence, such research and development activities of dendritic cell and tumor
cell vaccines are expected to impel the global dendritic cell and tumor cell
vaccines market growth.
Approvals of vaccines by
regulatory bodies are expected to drive the global dendritic cell and tumor
cell vaccines market growth. For instance, in June 2018, Northwest
BioTherapeutics received U.S. Food & Drug Administration (FDA) approval for
its dendritic cell vaccine, DCVax – L. It is being used for the treatment of
cancer type, glioblastoma. Its clinical study revealed that many patients
survived for over one and half years after the vaccination. Hence, such
approved vaccines based on dendritic cell are expected to drive the global
dendritic cell and tumor cell vaccine market growth.
Global Dendritic Cell and Tumor
Cell Vaccines Market Regional Analysis
North America is expected to be a
dominant region in the global dendritic cell and tumor cell vaccines market,
with increasing prevalence of cancer in the region. According to National
Institutes of Health (NIH) data, in 2018, around 609,640 people died due to
cancer and incidence rate was 439.2 per 100,000 men and women per year. The
most occurring cancer type are breast cancer, lung and bronchus cancer,
prostate cancer, colon and rectum cancer, melanoma of the skin, bladder cancer,
non-Hodgkin lymphoma, and kidney and renal pelvis cancer. Hence, the higher
prevalence of cancer may lead to higher demand for dendritic cell and tumor
cell vaccines and thereby, expected to propel the global dendritic cell and
tumor cell vaccine market growth.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/dendritic-cell-and-tumor-cell-cancer-vaccines-market-2753
Global Dendritic Cell and Tumor
Cell Vaccines Market Restraints
Withdrawal of dendritic cell and
tumor cell vaccines from its clinical trials are expected to hamper the global
dendritic cell and tumor cell vaccines clinical progress. For instance, in
March 2016, Istituto Scientifico Romagnolo per lo Studio e la cura dei Tumori,
conducted its clinical trial for dendritic cell vaccine with radiotherapy. It
was being studied for the treatment of renal cancer. However, it got withdrawn
in its second phase of clinical trial (reason unspecified). Hence, this factor
may have a negative impact on the global dendritic and tumor cell vaccine
market growth.
Global Dendritic Cell and Tumor
Cell Vaccines Market Key Players
Some of the major players
operating in the global dendritic cell and tumor cell vaccines market include,
JW CreaGene, Miltenyi Biotec, GlaxoSmithKline plc, NorthWest BioTherapeutics,
ImmunoCellular Therapeutics, Ltd., EnoChian Biosciences, Medigene AG, DC Prime,
Tella Incorporation, and CiMaas
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2753
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment